Michael R. Loebinger
Elite in Bronchiectasis

Michael R. Loebinger

London, ENG, GB 
Elite in Bronchiectasis
London, ENG, GB 
OverviewLocationsClinical Research

Overview

Michael Loebinger practices in London, United Kingdom. Mr. Loebinger is rated as an Elite expert by MediFind in the treatment of Bronchiectasis. His top areas of expertise are Bronchiectasis, Ciliary Dyskinesia-Bronchiectasis, Drug Induced Dyskinesia, and Allergic Bronchopulmonary Aspergillosis.

His clinical research consists of co-authoring 159 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 96 articles and participated in 2 clinical trials in the study of Bronchiectasis.

Gender
Male

Locations

London, ENG, United Kingdom
Other Locations
Harefield, ENG, United Kingdom
Brompton, ENG, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A 2x2 Factorial Randomized Open Label Trial to Determine the Clinical and Cost-effectiveness of Hypertonic Saline (HTS) 6% and Carbocisteine for Airway Clearance Versus Usual Care Over 52 Weeks in Bronchiectasis
A 2x2 Factorial Randomized Open Label Trial to Determine the Clinical and Cost-effectiveness of Hypertonic Saline (HTS) 6% and Carbocisteine for Airway Clearance Versus Usual Care Over 52 Weeks in Bronchiectasis
Enrollment Status: Completed
Publish Date: May 02, 2025
Intervention Type: Drug
Study Drugs: Hypertonic Saline, Carbocysteine
Study Phase: Phase 3
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Assess the Efficacy, Safety & Tolerability, and PK of INS1007 Administered Once Daily for 24 Weeks in Subjects With Non-CF Bronchiectasis - The Willow Study
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Assess the Efficacy, Safety & Tolerability, and PK of INS1007 Administered Once Daily for 24 Weeks in Subjects With Non-CF Bronchiectasis - The Willow Study
Enrollment Status: Completed
Publish Date: March 27, 2023
Intervention Type: Drug
Study Phase: Phase 2
View 1 Less Clinical Trial

159 Total Publications

Hypertonic Saline or Carbocisteine in Bronchiectasis.
Hypertonic Saline or Carbocisteine in Bronchiectasis.
Journal: The New England journal of medicine
Published: September 29, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Loebinger's expertise for a condition
ConditionClose
View All 7 Advanced Conditions
View All 10 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile